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A B S T R A C T
Cellular senescence, the irreversible loss of replicative capacity in somatic cells, plays a causal role in the de-
velopment of age-related pathology and in a number of age-related chronic inﬂammatory diseases. The ageing
lung is marked by an increasing number of senescent cells, and evidence is mounting that senescence may
directly contribute to a number of age-related respiratory diseases, including chronic obstructive pulmonary
disease (COPD) and idiopathic pulmonary ﬁbrosis (IPF). Telomere dysfunction and alterations in mitochondrial
homeostasis frequently occur in cellular senescence and are important to the development of the often detri-
mental senescence-associated secretory phenotype (SASP). The roles of telomeres, the mitochondria and cellular
senescence in lung ageing and disease are discussed. Therapeutic interventions targeting cellular senescence are
considered for delaying or potentially reversing age-related respiratory disease.
1. Introduction
Cellular senescence is generally deﬁned as irreversible cell-cycle
arrest. However, it is now accepted that senescence is a multifaceted
phenotype that includes time-dependent changes in global gene ex-
pression, epigenetic proﬁle and metabolism. Importantly, senescence is
characterised by the development of a pro-inﬂammatory secretory
phenotype, termed the senescence-associated secretory phenotype
(SASP)(Campisi & d'Adda di Fagagna, 2007). The SASP is thought to be
important for the immune-mediated clearance of senescent cells,
however, may also be a contributor to tissue dysfunction. Senescence
can be beneﬁcial: it acts as a tumour suppressor mechanism, inhibiting
the proliferation of potentially transformed cells, and has been
implicated in essential biological processes, such as wound healing,
tissue repair and embryonic development (van Deursen, 2014). How-
ever, evidence suggests that accumulation of senescent cells with time,
leads to age-related loss of tissue function (Baker et al., 2016; Baker
et al., 2011). Accordingly, senescent cells are found at sites of chronic
age-related disease (Munoz-Espin & Serrano, 2014) and have been
causally implicated in the development of osteoarthritis (OA) (Jeon
et al., 2017), atherosclerosis (Childs et al., 2016), liver steatosis
(Ogrodnik et al., 2017) and pulmonary ﬁbrosis (Schafer et al., 2017).
The lung is particularly aﬀected by the ageing process, showing clear
decline in structure and function with age (Janssens, Pache, & Nicod,
1999). Moreover, the ageing lung is characterised by the presence of
senescent cells and several respiratory diseases have been identiﬁed as
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diseases of accelerated lung ageing (Adnot et al., 2015; Mercado,
Ito, & Barnes, 2015). Chronic obstructive pulmonary disease (COPD)
and idiopathic pulmonary ﬁbrosis (IPF) are classic examples of re-
spiratory diseases that increase in prevalence with age and have been
associated with senescence (Amsellem et al., 2011; Birch et al., 2015;
Minagawa et al., 2011; Schafer et al., 2017; Tsuji, Aoshiba, & Nagai,
2006). Telomeres, the protective structures at the ends of linear chro-
mosomes, are particularly important to the senescence state and can
interact with other signiﬁcant regulators of the senescence phenotype,
including the mitochondria (Passos, Saretzki, & von Zglinicki, 2007).
Both telomere dysfunction and alterations in mitochondrial home-
ostasis occur in the lung with age and in several age-related respiratory
diseases. Understanding the mechanisms involved in these processes
and how they impact on senescence and its associated phenotypes could
be pivotal to the generation of therapies to dampen, or prevent, age-
associated lung disease.
2. Cellular senescence: the good, the bad and the ugly
Cellular senescence was ﬁrst described more than 50 years ago
following the observation that normal human ﬁbroblasts undergo a ﬁ-
nite number of divisions before ceasing to proliferate in culture, a
concept termed the ‘Hayﬂick Limit’ (Hayﬂick &Moorhead, 1961). It
was subsequently hypothesised that senescence is a barrier to malignant
transformation, since transformed cells proliferate indeﬁnitely
(Hayﬂick, 1965). There is now considerable evidence to support the
notion that senescence is a potent anti-cancer mechanism, both in
preventing malignant transformation and in limiting tumour progres-
sion (Kang et al., 2011; Serrano, Lin, McCurrach, Beach, & Lowe, 1997;
Sharpless, Ramsey, Balasubramanian, Castrillon, & DePinho, 2004;
Suram et al., 2012; Xue et al., 2007). In this context, the induction of
cellular senescence is believed to be a beneﬁcial process, something
which is supported by recent discoveries suggesting that short-term or
‘acute’ senescence is advantageous during embryonic development
(Munoz-Espin et al., 2013; Storer et al., 2013), wound healing and
tissue repair (Demaria et al., 2014; Krizhanovsky et al., 2008). How-
ever, with advanced age, senescent cells accumulate and evidence
suggests that senescent cells which remain for prolonged periods are
major drivers of age-related tissue deterioration and chronic age-related
disease (van Deursen, 2014). In this respect, senescent cells may be
beneﬁcial or deleterious to the organism, depending on context.
Cellular senescence is a complex process that can be induced by a
vast array of stressors. Replicative senescence occurs following pro-
longed periods of division leading to an eventual plateau in cell pro-
liferation. However, an increasing repertoire of senescence inducers is
continually being identiﬁed, which cause senescence prior to the onset
of replicative exhaustion, termed “stress-induced premature senes-
cence”; these include oncogenes, reactive oxygen species (ROS) and
cytotoxic compounds (Kuilman, Michaloglou, Mooi, & Peeper, 2010).
Cell cycle arrest is usually accompanied by the activation of a DNA
damage response (DDR), initiated by ataxia-telangiectasia mutated
(ATM) and AT and Rad3-related protein (ATR) kinases, then mediated
through activation of the tumour suppressor protein p53 and upregu-
lation of the cyclin-dependent kinase inhibitors (CDKis) p21CIP1,
p16INK4a or p14ARF (known as p19ARF in mice). The CDKis supress the
phosphorylation and inactivation of pRb leading to blockade of S-phase
entry and cell cycle arrest (Campisi & d'Adda di Fagagna, 2007) (Fig. 1).
While proliferation arrest is a major hallmark of senescent cells, these
cells are not inert; they are highly metabolically active and generally
continue to enlarge in size. In addition, senescent cells develop a se-
cretory phenotype, characterised by release of cytokines, chemokines,
growth factors and matrix remodelling proteases; the so-called SASP
(Coppe et al., 2008). The SASP can have potent eﬀects on neighbouring
cells and surrounding tissue, and on the very cells that produce it, thus
the SASP can act in both paracrine and autocrine fashions. Indeed, it
has been shown that the SASP can induce senescence in nearby healthy
cells, mediated by vascular endothelial growth factor (VEGF), mono-
cyte chemoattractant protein 1 (MCP-1) and CCL20 (Acosta et al.,
2013). Moreover, the SASP can reinforce both stress-induced, re-
plicative and oncogene-induced senescence (OIS) growth arrest via IL-6
and IL-8 signaling, in a self-amplifying secretory network (Acosta et al.,
2008; Kojima, Kunimoto, Inoue, & Nakajima, 2012). It is the potent
eﬀects of the SASP that likely implicate senescence in a range of bio-
logical processes. For instance, data suggests that cells with senescence-
like characteristics, including activity of the lysosomal enzyme senes-
cence-associated β-galactosidase (Sen-β-Gal) and p21 expression,
without detectable DDR activation, signal the immune system leading
to macrophage inﬁltration and clearance of senescent cells during
embryonic development, which contributes to tissue remodeling pro-
cesses (Munoz-Espin et al., 2013). The speciﬁc SASP components are
undeﬁned but are believed to involve transforming growth factor-β
(TGF-β). Similarly, evidence suggests that senescent tumour cells signal
and are cleared by the immune system, limiting liver carcinogenesis in
a process mediated by release of MCP-1 (Iannello, Thompson, Ardolino,
Lowe, & Raulet, 2013; Kang et al., 2011; Xue et al., 2007). Indeed, the
constituents of the SASP could diﬀer depending on the biological pro-
cess and the origin of the senescent cell. The SASP associated with se-
nescent ﬁbroblasts involved in cutaneous wound healing is char-
acterised by release of platelet-derived growth factor AA (PDGF-AA)
and proteases, such as matrix metalloproteinases (MMP) 2, 3 and 9,
which act to induce myoﬁbroblast diﬀerentiation to accelerate wound
closure and to limit ﬁbrosis occurring through rapid synthesis of ex-
tracellular matrix (ECM) (Demaria et al., 2014; Jun & Lau, 2010). Si-
milar results demonstrate that hepatic senescent cells act to limit liver
ﬁbrosis following acute liver injury through production of proteases
and activation of immune surveillance mechanisms (Krizhanovsky
et al., 2008). The composition of the SASP associated with ageing is
highly variable, likely since senescence occurs in a number of diﬀerent
cell types, in various organs, and in several organisms with age (Birch
et al., 2015; Dimri et al., 1995; Fumagalli et al., 2012; Herbig, Ferreira,
Condel, Carey, & Sedivy, 2006; Hewitt et al., 2012; Jeyapalan, Ferreira,
Sedivy, & Herbig, 2007; Krishnamurthy et al., 2004; C. Wang et al.,
2009). Furthermore, while senescence was initially believed to pre-
dominantly aﬀect cells with proliferative capacity, such as epithelial
cells and ﬁbroblasts, more recently senescent-like phenotypes have
been described in post-mitotic cells, including neurons, slowly-dividing
hepatocytes and in adipose tissue, suggesting that the contribution of
cellular senescence to the ageing process is more widespread than in-
itially conceived (Fumagalli et al., 2012; Jurk et al., 2012; Schafer et al.,
2016). Nevertheless, studies suggest that the consistently upregulated
SASP factors associated with senescence in ageing include IL-6, IL-1α,
plasminogen activator inhibitor 1 (PAI-1) and MCP-1 (Baker et al.,
2011; Baker et al., 2016; Childs et al., 2016). The mechanisms under-
lying senescent cell accumulation with ageing are incompletely un-
derstood. However, an age-associated reduction in immune system
function leading to impaired senescent cell clearance is one probable
factor (Ovadya & Krizhanovsky, 2014). While age-related increases in
senescent cell frequencies have been observed for some time, only re-
cently has senescence been causally implicated in the ageing process.
Using a transgenic mouse model (INK-ATTAC), Baker and colleagues
found that elimination of p16INK4a-positive senescent cells delayed the
onset of age-related pathologies including sarcopenia, loss of adipose
tissue and cataracts in both progeroid (BubR1 (mitotic checkpoint ki-
nase budding uninhibited by benzimidazole-related 1) insuﬃcient
mice) and wild-type mice and increased lifespan of wild-type mice
(Baker et al., 2011; Baker et al., 2016). Senescent cells may contribute
to a loss of tissue homeostasis and impaired organ function through a
reduction in regenerative capacity of tissues due to proliferative arrest
(Choudhury et al., 2007) or through altering functions of surrounding
cells and tissues by the deleterious properties of the SASP, such as the
pro-inﬂammatory aspects (Ovadya & Krizhanovsky, 2014). Indeed, and
paradoxically, cellular senescence can contribute to malignant
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transformation and cancer progression by promoting transformation
and invasiveness of pre-malignant cells through the factors they release
(Coppe et al., 2008). Additionally, the secretome of senescent stromal
cells can stimulate growth, angiogenesis and epithelial-to-mesenchymal
transition (EMT); all of which can promote malignancy (Capparelli
et al., 2012; Coppe et al., 2008; Coppe, Kauser, Campisi, & Beausejour,
2006). The SASP can also generate an inﬂammatory environment,
which is believed to be a factor by which senescent cells may contribute
to ‘inﬂammaging’ and to the development of chronic age-related dis-
eases. Indeed, senescent cells have been found in the articular cartilage
from patients with OA, in the brains of patients with Alzheimer’s dis-
ease and in atherosclerotic lesions (McShea, Harris, Webster,
Wahl, & Smith, 1997; Price et al., 2002; Vasile, Tomita, Brown,
Kocher, & Dvorak, 2001; J. Wang et al., 2015). Interestingly, a recent
study demonstrated that transplantation of senescent cells into the knee
joints of mice induces an OA-like-phenotype (M. Xu et al., 2016).
Furthermore, OA occurring following cruciate ligament injury is pre-
ceded by the accumulation of senescent cells in the knee joint of mice
and selective elimination of senescent cells by either genetic or phar-
macological means prevents the development of post-traumatic OA in
mice (Jeon et al., 2017). Similarly, clearance of senescent cells in mice
prone to atherosclerosis reduces formation and progression of athero-
sclerotic plaques and inhibits processes that promote plaque rupture
(Childs et al., 2016). While evidence suggests that senescent cells are
causal to the development of some age-related diseases, whether the
SASP per se plays a causal role in the process is more challenging to test
experimentally, particularly given its heterogeneity. Despite this, ge-
netic and pharmacological removal of senescent cells leads to a con-
comitant decrease in commonly described SASP factors, such as IL-6,
tumour necrosis factor (TNF)-α, IL-1α, and MCP-1 in tissues that show
functional improvements in age-associated pathologies (Baker et al.,
2011; Baker et al., 2016; Childs et al., 2016). This suggests that ame-
lioration of senescence-associated inﬂammation could be leading to
beneﬁcial eﬀects and that targeting the SASP could oﬀer therapeutic
potential for age-associated pathologies and age-related diseases.
3. Cellular senescence in lung ageing and disease
Lung maturity typically peaks between the ages of 20 and 25 years,
and then undergoes an age-progressive decline in function with re-
ductions in forced expiratory volume in 1 second (FEV1), forced vital
capacity (FVC), with progressively more ineﬃcient gas exchange across
Fig. 1. Pathways involved in senescence induction. Senescent cell
cycle arrest is usually triggered by the activation of a DNA damage
response (DDR), initiated by ataxia-telangiectasia mutated (ATM) and
AT and Rad3-related protein (ATR) kinases leading to the formation
of DNA damage foci, characterised by modiﬁcation of histone pro-
teins, such as the phosphorylation of histone 2A.X. This then impacts
on the p53-p21 and p16/p14-pRB tumour suppressor pathways. ATM
and ATR kinases phosphorylate and stabilise p53, which establishes
senescence by inducing expression of the cyclin-dependent kinase
inhibitor p21. p14 (p19 in mice) also stabilises p53 by inhibiting the
ubiquitin ligase mouse double minute 2 (MDM2). p21 supresses the
phosphorylation and inactivation of pRb, leading to cell cycle arrest.
pRb halts cell proliferation by inhibiting the activation of E2F, a
transcription factor required for the expression of cell-cycle progres-
sion genes. Cell cycle arrest is maintained by p16, which is tran-
scriptionally upregulated under the control of p38 mitogen-activated
protein kinase (p38MAPK), and also supresses pRB inactivation by
inhibiting CDK4 and CDK6. Chk1/2, checkpoint kinase 1/2; CDK,
cyclin-dependent kinase inhibitor.
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the alveolar wall. In addition, a range of physiological changes occur in
the ageing lung, including alveolar dilatation and distal airspace en-
largement (emphysema) and loss of supporting tissue for peripheral
airways (Janssens et al., 1999). This is associated with an increase in
compliance as well as pathogenic susceptibly to pulmonary diseases (L.
Wang, Green, Smiley-Jewell, & Pinkerton, 2010). Despite this, some of
the mechanisms underlying lung ageing remain elusive. A number of
studies have shown that cells positive for senescence-associated mar-
kers, such as the DDR protein γH2A.X, the heterochromatin protein
macro H2A (mH2A) and the CDKis p21 and p16 accumulate in the
murine lung during physiological ageing, including in the alveoli
(Kreiling et al., 2011; C. Wang et al., 2009), the airway epithelium
(Birch et al., 2015), in vascular smooth muscle cells (Calhoun et al.,
2016) and in lysates of whole murine lung (Kreiling et al., 2011;
Krishnamurthy et al., 2004). In addition, several factors associated with
the SASP, in particular TGF-β and IL-6 increase in the murine lung with
age (Calhoun et al., 2016). In contrast, the role of senescence during
lung ageing in humans is less well deﬁned. Using whole tissue lysates,
one group described increased p16 and mH2A in the lungs of older
humans (Shivshankar, Boyd, Le Saux, Yeh, & Orihuela, 2011). Another
study has demonstrated that mH2A and p16 increase in the lungs of
humans between 50 and 60 years of age, as compared to 20-30-year-old
persons, with expression predominantly increasing in the vasculature
(Calhoun et al., 2016). Interestingly, in the murine lung, senescent cell
frequencies correlate with changes in lung structure, such as emphy-
sematous-like changes (Birch et al., 2015) and deposition of collagen
(Calhoun et al., 2016). However, it is unclear if senescent cells causally
contribute to lung dysfunction or are merely associated with it. Recent
work from Hashimoto et al. provides evidence that senescent cells are
indeed responsible, at least in part, for the age-associated decline in
lung function. Using a transgenic mouse model whereby naturally oc-
curring p19ARF-positive cells could be eliminated by a toxin-mediated
cell knockout system, it was demonstrated that removal of p19ARF-po-
sitive cells from the lungs of 12-month-old mice abolished expression of
senescence-associated markers and restored lung compliance, structure,
and elasticity (Hashimoto et al., 2016). These ﬁndings suggest that
cellular senescence is causal to physiological lung ageing and could
potentially be targeted to combat age-associated phenotypes in the lung
or indeed development of diseases associated with lung ageing. A
number of respiratory diseases are classiﬁed as diseases of accelerated
lung ageing, with cellular senescence thought to contribute to their
development and pathophysiology.
COPD is one such age-related disease and one of the most common
respiratory conditions globally, causing chronic morbidity and high
mortality (Mannino & Buist, 2007). COPD is typically characterised by
imbalances in inﬂammatory processes and repair events, aﬀecting both
the peripheral airways and lung parenchyma and leading to structural
changes, including peri-airway ﬁbrosis and destruction of alveolar
airspaces (Barnes, 2016a, 2016b; Chung & Adcock, 2008). Thus patients
often have a combination of chronic bronchitis and emphysema. Some
of the structural changes that occur in the COPD lung reﬂect those
which occur during normal lung ageing. Indeed, the decline in lung
function that occurs as COPD progresses resembles that which occurs
during ageing, however at a more advanced rate (Fletcher & Peto, 1977;
K. Ito & Barnes, 2009). In accordance with accelerated ageing processes
taking place in COPD, a number of studies have described increased
markers of senescence in the COPD lung. Higher percentages of alveolar
type II cells and pulmonary vascular endothelial cells positive for p16
and p21 expression have been observed in lung tissue from patients
with COPD (Amsellem et al., 2011; Aoshiba &Nagai, 2009; Birch et al.,
2015; Tsuji et al., 2006; Tsuji, Aoshiba, & Nagai, 2010). Similarly, there
are signiﬁcantly more DNA damage foci in type I and type II alveolar
epithelial cells, airway epithelial cells and endothelial cells in the lungs
of patients with COPD (Aoshiba, Zhou, Tsuji, & Nagai, 2012; Birch
et al., 2015). Cells isolated from and cultured outside of the COPD lung,
such as pulmonary vascular endothelial cells and airway epithelial cells,
retain markers of senescence including, Sen-β-Gal activity and high p21
and p16 mRNA expression (Amsellem et al., 2011; Birch et al., 2015).
Similarly, lung ﬁbroblasts from patients with advanced COPD appear
senescent in culture, exhibiting reduced proliferation capacity and Sen-
β-Gal activity (Holz et al., 2004; Muller et al., 2006). Moreover, ci-
garette smoke exposure, the main risk factor for COPD, induces senes-
cence-associated phenotypic changes in vitro. In cultured alveolar epi-
thelial cells, cigarette smoke extract (CSE) causes growth arrest, an
enlarged cellular morphology, Sen-β-Gal activity and increased p21
expression (Tsuji, Aoshiba, & Nagai, 2004). Similar ﬁndings have been
reported in lung ﬁbroblasts, with CSE exposure leading to an enlarged
and ﬂattened morphology, increased Sen-β-Gal activity, increased p16
expression and premature cell-cycle arrest (Aoshiba & Nagai, 2009;
Birch et al., 2015; Nyunoya et al., 2006). Long-term exposure to CSE
(35 days) also triggers a surge in release of key SASP factors IL-6 and IL-
8 (Aoshiba &Nagai, 2009; Birch et al., 2015; Nyunoya et al., 2006).
Cigarette smoke exposure triggers H2A.X phosphorylation in normal
bronchial epithelial cells in vitro (Albino et al., 2004; Birch et al., 2015)
and in vivo (Birch et al., 2015) while also increasing levels of p16 in the
lungs and nasal cavity, as determined using a p16-luciferase reporter
mouse model (Sorrentino et al., 2014). The eﬀects of senescent cells in
chronic lung diseases are two-fold; 1) the accumulation of cells ex-
hibiting limited replicative potential would impair lung tissue main-
tenance and repair, promoting progressive destruction of the lung and
likely explaining lung function decline in COPD and 2) by contributing
to a pro-inﬂammatory and pro-ageing environment via SASP factor
release and bystander eﬀects. To this end, the chronic inﬂammatory
processes that occur in the lungs of patients with COPD, and those that
are detectable in the circulation, involve many inﬂammatory cytokines
akin to the SASP, including IL-1, IL-6, CXCL8, TNF-α, TGF-β and pro-
teases such as MMP2 and MMP9 (Aldonyte, Jansson,
Piitulainen, & Janciauskiene, 2003; Bhowmik, Seemungal,
Sapsford, &Wedzicha, 2000; Keatings, Collins, Scott, & Barnes, 1996;
Russell et al., 2002; Song, Zhao, & Li, 2001). Therefore, the SASP may
contribute to lung structural alterations and may promote senescence in
surrounding cells. The potent eﬀects of the SASP could also extend to
extra-pulmonary environments, contributing to systemic complications
and co-morbidities of which there are many associated with COPD,
including sarcopenia, insulin resistance and kidney dysfunction (Boyer
et al., 2015). While current data does not deﬁnitively implicate cellular
senescence and the SASP as causal to COPD, understanding the un-
derlying mechanisms involved in COPD-associated senescence could be
important for development of therapies to dampen COPD progression.
Similarly to COPD, IPF is a progressive and fatal lung disease clas-
sically dubbed a ‘disease of ageing’ but contrastingly is characterised by
ﬁbrosis of the interstitium, leading to scarring of the lung parenchyma,
with limited airway-centered pathology (Alder et al., 2008; Alder et al.,
2011; Minagawa et al., 2011; Raghu, Weycker, Edelsberg,
Bradford, & Oster, 2006). While IPF occurs more commonly with age,
the underlying mechanisms are still poorly understood. However, a
number of studies implicate cellular senescence processes in IPF pa-
thogenesis. It has been described that in the bronchial epithelium of
patients with IPF, there is an increased number of cells positive for p21
and Sen-β-Gal activity (Minagawa et al., 2011). Similar ﬁndings have
been described in alveolar epithelial cells of the IPF lung (Kuwano
et al., 1996) and in ﬁbroblasts isolated from the lungs of IPF patients
(Yanai et al., 2015). A recent study describes increased p16 and p21
levels in alveolar epithelial cells present in ex vivo lung tissue from
patients with IPF, with p16 levels negatively correlating with diﬀusing
capacity of the lung for carbon monoxide, suggesting that p16 levels
correlate with disease severity (Lehmann et al., 2017). Indeed, another
recent study reports a severity-dependent increase in p16 in the lungs of
patients with IPF (Schafer et al., 2017). Moreover, ex vivo models of
pulmonary ﬁbrosis are characterized by increased senescent alveolar
type II cells and elevated levels of key SASP factors (Lehmann et al.,
2017). Intratracheal delivery of bleomycin, a chemotherapeutic drug,
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induces lung ﬁbrosis in mice with similar features to human IPF, along
with increased frequencies of senescent alveolar epithelial cells and
ﬁbroblasts (Aoshiba, Koinuma, Yokohori, & Nagai, 2003; Schafer et al.,
2017) and increased levels of key SASP factor PAI-1 (W. T. Huang et al.,
2015). Interestingly, accumulation of senescent myoﬁbroblasts in the
lungs of aged mice following bleomycin injury is associated with an
impaired capacity for resolution of ﬁbrosis (Hecker et al., 2014), sug-
gesting that the presence of senescent cells is causal to the ﬁbrotic
phenotype in IPF. Indeed, a more recent proof-of-concept study causally
implicates cellular senescence in IPF pathogenesis and demonstrates the
therapeutic potential of senescence-targeted therapies or ‘se-
notherapies’ for pulmonary ﬁbrosis. Schafer and colleagues showed that
clearance of p16-positive senescent cells in the INK-ATTAC genetic
mouse model improves lung function, body composition and physical
health of mice treated with bleomycin to induce pulmonary ﬁbrosis
(Schafer et al., 2017). Notably, removal of senescent cells reduced ex-
pression of SASP factors with established roles in regulating ﬁbrotic and
pulmonary aspects of IPF, including IL-6, TGF-β and MMP12, sug-
gesting the SASP is a major mediator of IPF pathology. Moreover,
treatment of mice with drugs that induce apoptosis speciﬁcally in se-
nescent cells, termed senolytics, mirrored the results observed with
transgenic cell clearance (Schafer et al., 2017). While Schafer and
colleagues report no observable reduction in lung ﬁbrosis per se fol-
lowing senescent cell elimination, another recent study reported that
pulmonary ﬁbrosis, induced in mice following irradiation, was reversed
following treatment with ABT-263, a senolytic agent that selectively
killed senescent type II alveolar epithelial cells (Pan et al., 2017). This
suggests that targeting senescent cells is a plausible therapy for IPF,
both for improving physical health, and in limiting ﬁbrotic lesions.
COPD and IPF increase with age and occur later in life (Faner, Rojas,
Macnee, & Agusti, 2012). Therefore it is unsurprising that senescence
processes are activated in the COPD and IPF lung. However, why COPD
and IPF are so phenotypically diﬀerent, despite both being character-
ized by the presence of senescent cells, is poorly understood. So far,
studies in mouse models where an IPF-like phenotype can be induced
by bleomycin, support the concept that senescence is a contributor to
the process. However, in the context of COPD, such experiments have
not been conducted. Moreover, some patients with IPF also have COPD-
associated changes such as emphysema and this overlap syndrome has
been termed combined pulmonary ﬁbrosis emphysema (CPFE), which is
often accompanied by pulmonary hypertension and lung cancer, and
has a poor prognosis (Lin & Jiang, 2015). Although the mechanisms are
poorly understood, it may reﬂect a common pathogenetic pathway,
such as cellular senescence, which should be investigated further using
models to determine causality, as discussed above. More in-depth in-
vestigation into the roles of senescence in other respiratory diseases, not
typically associated with ageing, is also required. For instance, cells
with senescence-like properties, including p16 and p21 expression, in-
crease in the airway epithelium of patients with cystic ﬁbrosis (CF)
(Fischer et al., 2013) and bronchiectasis (Birch et al., 2016). CF patients
suﬀer recurrent inﬂammation in the lung from an early age, resulting in
decline in lung function (Elborn, 2016), whereas bronchiectasis typi-
cally aﬀects the adult population and can occur in conjunction with CF
or can develop independently of CF, commonly following childhood
respiratory infection (O'Donnell, 2008). Both CF and bronchiectasis are
characterised by cycles of infection and chronic inﬂammation. Our
group has previously demonstrated that the ageing process and cellular
senescence are accelerated under conditions of chronic low-grade in-
ﬂammation (Jurk et al., 2014). Using a mouse model whereby nuclear
factor-κB (NF-κB) activity is enhanced due to knockdown of the in-
hibitory nfkb1 subunit (nfkb1−/−), it was found that markers of cellular
senescence were increased in the gut and liver (Jurk et al., 2014).
Moreover, nfkb1−/− mice showed signs of premature ageing including
fur loss and greying, epidermal thinning and cachexia (Jurk et al.,
2014). This is not the ﬁrst report of inﬂammatory processes impacting
on rates of cellular senescence. A previous study using the same nfkb1−/
− mice reported increased frequencies of hepatocytes harboring telo-
mere damage, a major hallmark of senescent cells, in hepatocellular
carcinoma, which could be reduced upon neutrophil-speciﬁc depletion
(Wilson et al., 2015). Moreover, other pro-inﬂammatory stimuli, such
as neutrophil elastase, induce senescence in vitro (Fischer et al., 2013).
Given the results of these studies, it is highly plausible that chronic
inﬂammatory processes occurring in the lungs of patients with CF and
bronchiectasis may lead to senescence induction, which could act in a
vicious cycle to perpetuate inﬂammation, via the SASP and paracrine
eﬀects, contributing to disease progression and chronicity. The under-
lying mechanisms involved in senescence occurring in bronchiectasis
and CF should be elucidated further. The concept of inﬂammation-in-
duced senescence may also be relevant to asthma; a disease of airway
hyper-responsiveness characterised by chronic inﬂammation and
structural alterations to the airways (Burrows, Martinez, Halonen,
Barbee, & Cline, 1989; Halwani, Al-Muhsen, & Hamid, 2010). It has
been shown that p16 and p21 are increased in the airway epithelium of
adult patients with asthma with loss of proliferation marker Ki67 (Wu
et al., 2013). Additionally, cellular senescence was induced in the
airway epithelium of a mouse model of asthma following chronic al-
lergen exposure (Wu et al., 2013). Senescence-related changes are not
only present in the lungs of adults with asthma, with senescence mar-
kers including p21 and loss of Ki67 already detectable in the airways of
asthmatic children (Fedorov, Wilson, Davies, & Holgate, 2005). There-
fore understanding whether and what senescence-associated pathways
are involved in the pathogenesis of asthma may assist in the develop-
ment of therapeutics.
4. Telomeres and the mitochondria: major players in senescence
4.1. The role of telomeres in senescence
Telomeres are specialised structures consisting of repetitive DNA
(5′-TTAGGG-3′) repeats, which function to protect the ends of linear
chromosomes from erosion or fusion by DNA repair processes
(Blackburn, 1991). Telomeres progressively shorten with each cell di-
vision due to the “end-replication problem”, whereby standard DNA
polymerases are unable to synthesise DNA in a 3′-5’ direction, leading
to incomplete replication of the lagging strand. Telomere shortening
was shown to be causal to replicative senescence when ectopic ex-
pression of the catalytic subunit of telomerase, which maintains telo-
mere length, prevented senescence of normal human ﬁbroblasts in vitro
(Bodnar et al., 1998). The progressive loss of telomere repeats during
replicative senescence destabilises the telomere structure, which is
usually arranged in a telomere loop conformation by a complex of six
proteins: telomeric repeat binding factor 1 (TRF1), telomeric repeat
binding factor 2 (TRF2), TRF2 interacting protein (RAP1), TRF1-in-
teracting nuclear factor 2 (TIN2), adrenocortical dysplasia protein
homolog (TPP1) and protection of telomeres 1 (POT1); collectively
known as shelterin (de Lange, 2005; Griﬃth et al., 1999). Loss of
shelterin due to telomere shortening “telomere uncapping” has been
shown to trigger a classical DDR due to exposure of the telomere end
and recognition by the DNA repair machinery as a double-strand break,
leading to cell-cycle arrest (d'Adda di Fagagna et al., 2003). Indeed, it
was shown that replicatively senescent human ﬁbroblasts accumulate
proteins involved in the DDR at telomere regions, including γH2A.X,
53BP1, MDC1 and NBS1 (d'Adda di Fagagna et al., 2003). Telomere
shortening is not solely dictated by the end-replication problem how-
ever, with studies showing that the rate of telomere shortening, and
therefore induction of senescence, can be accelerated by oxidative
stress (Richter & von Zglinicki, 2007; von Zglinicki, 2002). Accordingly,
telomeres are known to be particularly sensitive to oxidative stress,
acquiring oxidative single-strand damage at a much faster rate than the
bulk of the genome, possibly due to the high content of guanine triplets
(Henle et al., 1999; Petersen, Saretzki, & von Zglinicki, 1998). This,
coupled with the fact that repair of telomere damage is inhibited by
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components of the shelterin complex, in order to prevent telomere fu-
sions, places telomeres as key inducers of cellular senescence
(Bae & Baumann, 2007; Smogorzewska & de Lange, 2002). Indeed, our
group and others have demonstrated that while the great majority of
DDR foci are resolved soon after their formation, telomere-associated
damage is relatively long-lived (Fumagalli et al., 2012; Hewitt et al.,
2012). Furthermore, our group have shown that genotoxic and oxida-
tive damage induces a DDR at telomere regions, referred to as telomere-
associated DNA damage foci (TAF), in a length-independent and telo-
merase-independent manner, suggesting that loss of shelterin may not
be a requirement for telomere-induced senescence (Hewitt et al., 2012).
Telomere dysfunction fuels persistent DDR signalling and is therefore
considered particularly important to senescence and its associated
phenotypes. For instance, it has been shown that persistent DDR sig-
nalling is required for release of key SASP factors, such as IL-6, with
transient DDR activation having little eﬀect on IL-6 release (Rodier
et al., 2009). Mechanistically, ATM activation, a key event in DDR
signalling, leads to activation of NEMO which then activates the IKK
complex resulting in nuclear translocation of NF-κB, the major factor
regulating transcription of many SASP-associated components
(McCool &Miyamoto, 2012). However, other evidence suggests that the
SASP can be inﬂuenced by DDR-independent mechanisms, such as
through activation of p38MAPK, which then increases transcriptional
activity of NF-κB (Freund, Patil, & Campisi, 2011), or through cytosolic
DNA sensing leading to upregulation of interferon-stimulated genes that
drive the production of inﬂammatory SASP components (Gluck et al.,
2017).
4.2. Telomere-mitochondria crosstalk in senescence
Telomere damage may also impact on senescence and associated
phenotypes via the mitochondria (Fig. 2). The mitochondria are the
main generators of reactive oxygen species (ROS) within the cell. Our
group have previously shown that activation of a DDR can induce mi-
tochondrial ROS generation via signalling pathways involving ATM,
p21 and the mechanistic target of rapamycin (mTOR) (Correia-Melo
et al., 2016; Passos et al., 2010). We reported that changes in mi-
tochondrial size and ROS production were dependent on PGC-1β-de-
pendent mitochondrial biogenesis. In contrast, it has been documented
that short telomeres signal and activate p53, which represses PGC-1α
and PGC-1β promoters, leading to mitochondrial dysfunction (Sahin
et al., 2011). Conversely, telomerase, the enzyme responsible for
maintaining telomere length, may impact directly on mitochondrial
function since the reverse transcriptase component (TERT) can trans-
locate to the mitochondria under conditions of mild oxidative stress and
protect mitochondrial function by reducing ROS, protecting mi-
tochondrial DNA (mtDNA) and increasing mitochondrial membrane
potential (Ahmed et al., 2008).
On the other hand, mitochondria can inﬂuence DDR signalling and
potentiate telomeric damage; mitochondrial-derived ROS are involved
in induction and maintenance of senescence through feedback loops
replenishing DNA damage and maintaining the DDR and senescence
(Passos et al., 2007; Passos et al., 2010). Moreover, mitochondrial ROS
can lead to the generation of single-strand breaks in telomere regions,
with the mitochondrial-targeted antioxidant Mito-Q being able to re-
duce telomere shortening and increase replicative lifespan of ﬁbroblasts
under mild oxidative stress (Saretzki, Murphy, & von Zglinicki, 2003).
Additionally, mild chronic uncoupling of mitochondria, which reduces
accumulation of mitochondrial superoxide, improves telomere main-
tenance and extends telomere-dependent lifespan (Passos et al., 2007).
On the other hand, FCCP treatment, which causes severe mitochondrial
depolarisation and thus mitochondrial dysfunction, increases ROS
generation and leads to telomere attrition and chromosome fusions in
murine embryos, further supporting a role for mitochondrial dysfunc-
tion impacting on telomere health (Liu, Trimarchi, Smith, & Keefe,
2002).
4.3. The role of the mitochondria in senescence
The mitochondria can impact on aspects of the senescence pheno-
type in a number of possible ways and it has been suggested that dys-
functional mitochondria are an additional feature of senescent cells that
enable them to mediate paracrine eﬀects (Birch & Passos, 2017;
Korolchuk, Miwa, Carroll, & von Zglinicki, 2017). Therefore, crosstalk
between telomeres and the mitochondria may have knock-on eﬀects on
a number of pathways that regulate senescence.
4.3.1. Are the mitochondria causal to senescence?
Mitophagy, the selective degradation of defective mitochondria by
autophagy, is reduced in senescent cells (Garcia-Prat et al., 2016). This
could, in part, be responsible for the increase in mitochondrial mass
that has been described in senescence both in vitro and in vivo (Correia-
Melo et al., 2016; Passos et al., 2010). mTOR-dependent mitochondrial
biogenesis may also play a role, since treatment of cells and mice with
rapamycin, an inhibitor of mTOR, reduces mitochondrial mass (Correia-
Melo et al., 2016). Moreover, a reduction in mitochondrial ﬁssion
events in senescent cells contributes to increased connectivity of the
mitochondrial network (Dalle Pezze et al., 2014). The accumulation of
the mitochondrial compartment and of dysfunctional mitochondria in
particular, may be an important contributor to the pro-inﬂammatory
aspects of cellular senescence. It has been shown that mitochondrial
dysfunction induced by mtDNA depletion, knockdown of mitochondrial
sirtuin 3 (SIRT3) or through inhibition of the electron transport chain
Fig. 2. Crosstalk between telomeres and the mitochondria. Damage at telomere regions,
either due to telomere shortening or length-independent damage, elicits a DNA damage
response (DDR) in a similar manner to double-strand breaks (DSBs). Activation of ATM
kinase can impact on mTOR activity via AKT kinase and p21 leading to PGC-1β-depen-
dent mitochondrial biogenesis and associated ROS generation. The activation of p53 can
also impact on PGC-1α and PGC-1β, leading to mitochondrial dysfunction.
Mitochondrial-derived ROS can feedback and directly aﬀect DDR signalling by re-
plenishing damage at genomic and telomere regions. Telomerase, the enzyme responsible
for maintaining telomere length, may impact directly on mitochondrial function since the
reverse transcriptase component (TERT) can translocate to the mitochondria under
conditions of mild oxidative stress and reduce ROS, protecting mitochondrial DNA
(mtDNA) and increasing mitochondrial membrane potential. ATM, ataxia-telangiectasia
mutated; mTOR, mechanistic target of rapamycin; ROS, reactive oxygen species.
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(ETC) induces senescence with a distinct phenotype, termed MiDAS
(mitochondrial dysfunction-associated senescence) (Wiley et al., 2016).
Our group recently designed a proof-of-principle experiment, which
interrogated whether mitochondria are truly necessary for senescence.
Utilising the parkin-mediated mitophagy system to completely remove
mitochondria upon their depolarisation, we found that following a
variety of senescence triggers (e.g. oxidative stress and oncogene acti-
vation) features of cellular senescence, including Sen-β-Gal activity and
the SASP, were suppressed (Correia-Melo et al., 2016). Paradoxically,
despite decreases in p21 and p16, mitochondrial clearance did not
rescue cell-cycle arrest. Additionally, treating senescent cells with ra-
pamycin supresses the senescence phenotype, including major SASP
components, in a similar fashion to mitochondrial clearance by im-
pacting on mTOR-driven PGC1-β-dependent mitochondrial biogenesis
(Correia-Melo et al., 2016). This suggests that mTOR can regulate the
SASP through mitochondria-dependent mechanisms. Indeed, data sug-
gest that mTOR has an important role in regulating mitophagy; it has
been described that reduced mTOR activity limits ROS generation
within the cell by increasing autophagic ﬂux and mitochondrial mem-
brane potential, thereby extending replicative lifespan of ﬁbroblasts
(Lerner et al., 2013). The mitochondria may therefore be key to the
regulation of some aspects of cellular senescence, such as the pro-in-
ﬂammatory phenotype, and may be promising targets for SASP mod-
ulation (Birch & Passos, 2017). Additionally, data suggests that mTOR
can regulate the SASP by mechanisms independent of the mitochondria.
For instance, mTOR has been shown to regulate the translation of
MAPKAPK2 kinase, which phosphorylates and inhibits the RNA binding
protein ZFP36L1 during senescence, limiting its ability to degrade
mRNA transcripts of numerous SASP factors (Herranz et al., 2015).
mTOR also promotes translation of certain early SASP factors, including
IL-1α, which is a membrane bound cytokine that can promote activity
of NF-κB (Laberge et al., 2015).
4.3.2. Do alterations in mitochondrial metabolism impact on senescence?
How the mitochondria may regulate the SASP needs to be fully
elucidated. A number of studies provide evidence to suggest that the
metabolic state of the cell is drastically shifted in senescence and may
inﬂuence senescence-associated inﬂammation (Wiley & Campisi, 2016).
For example, senescent cells have enhanced glycolytic activity, with
relatively less ATP being generated by oxidative phosphorylation
(Zwerschke et al., 2003). Increases in AMP:ATP and ADP:ATP ratios
have been linked to senescence induction; AMP-activated protein ki-
nase (AMPK) is a regulator of cellular responses to energy stress and is
activated by increased AMP and ADP, which then regulates a series of
responses including mitochondrial biogenesis (Hardie, Ross, & Hawley,
2012). AMPK activation can also lead to phosphorylation and activation
of p53, promoting cell-cycle arrest via transcriptional upregulation of
p21 (Jiang, Du, Mancuso, Wellen, & Yang, 2013) and can inhibit HuR-
dependent degradation of p21 and p16 mRNA (W. Wang, Yang, Lopez
de Silanes, Carling, & Gorospe, 2003). Additionally, a low NAD+/
NADH ratio leading to AMPK activation was proposed as a mechanism
mediating MiDAS, in the aforementioned study (Wiley et al., 2016).
Low NAD+/NADH ratios have also been shown to promote senescence
by impacting on NAD+-dependent poly-ADP ribose polymerase (PARP)
activity, the main repairers of genotoxic stress-induced damage. In-
hibition of PARP-1 maintains DNA damage and sensitises cells to se-
nescence in vitro (Eﬁmova et al., 2010). NAD+ is also a co-factor for
Sirtuins, a family of histone and protein deacetylases. Sirtuins impact
on senescence in various ways, including regulating NF-κB activity and
in maintaining transcriptionally silent chromatin of NF-κB-dependent
genes, such as SASP factor transcripts (Haigis & Sinclair, 2010). In-
cidentally, Sirtuin levels are reduced in senescent cells (Sasaki, Maier,
Bartke, & Scrable, 2006). Alterations in tricarboxylic acid (TCA) cycle
activity have also been described in cellular senescence, however the
extent to which this occurs is still not fully understood (Fig. 3). In OIS,
pyruvate dehydrogenase (PDH) kinase 1 is suppressed, leading to
increased activity of PDH and enhanced usage of pyruvate in the TCA
cycle (Kaplon et al., 2013). In contrast, pyruvate assists in scavenging
ROS and contributes to cellular anti-oxidant defences (Desagher,
Glowinski, & Premont, 1997). However, the role of pyruvate in oxidant
defence in senescence is unknown. Interestingly, pyruvate supple-
mentation at superphysiological levels limits the replicative lifespan of
ﬁbroblasts in vitro (D. Xu & Finkel, 2002). Malate metabolism has also
been implicated in senescence regulation, with loss of mitochondrial
malic enzyme 2 (ME2) inducing senescence (Jiang et al., 2013). Ad-
ditionally, overexpression of ME2 extends replicative lifespan of ﬁbro-
blasts. Mechanistically, ME2 depletion increases ROS, leading to AMPK-
dependent p53 activation and senescence induction (Jiang et al., 2013).
Thus, malate metabolism may be involved in senescence by regulating
anti-oxidant defences. Whether malate metabolism is involved in SASP
regulation is undetermined. Interestingly, macrophages activated by
pro-inﬂammatory stimuli undergo metabolic reprogramming, whereby
mitochondria shift to a more glycolytic state and produce ROS, pro-
moting a pro-inﬂammatory response (Mills et al., 2016), directly
linking mitochondrial metabolism to pro-inﬂammatory cellular re-
sponses. Therefore, it is possible that shifts in mitochondrial metabo-
lism could be important in SASP regulation; understanding metabolic
control of senescence and the SASP may be crucial for development of
therapies for age-related disease.
4.3.3. Mitochondrial damage-associated molecular patterns
Dysfunctional mitochondria release multiple forms of damage-as-
sociated molecular patterns (DAMPS), such as ATP and mtDNA.
Similarly to pathogenic stimuli, mtDNA can activate innate immune
receptors, known as pattern recognition receptors (PRRs). Therefore
when present outside of the mitochondrial matrix, mtDNA is an im-
munostimulatory factor. Indeed, several signalling pathways sense
mtDNA in the cytoplasm, including the NLRP3 inﬂammasome, which
converges on NF-κB leading to production of pro-inﬂammatory cyto-
kines IL-1β and IL-18 (Horng, 2014). The cytosolic sensor of DNA: the
cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes
(STING) pathway also senses mtDNA that has leaked into the cyotsol,
which ultimately leads to type I interferon responses and an anti-viral
innate immune response (West et al., 2015). Recently, the cGAS-STING
pathway has been identiﬁed as a crucial regulator of senescence and the
SASP, which is engaged in response to cytosolic chromatin fragments
(CCFs) occurring due to Lamin B1 degradation in senescence, leading to
production of inﬂammatory SASP factors (Gluck et al., 2017). Whether
mtDNA plays a role in cGAS-STING-mediated SASP regulation is yet to
be assessed. However, it has been shown that in cells lacking mtDNA,
key SASP factors are attenuated (IL-1-depdendent arm) while other
features of the senescence phenotype are present, such as Sen-β-Gal
activity, suggesting that mtDNA might have some involvement in SASP
regulation (Wiley et al., 2016). However, whether mtDNA leakage oc-
curs in senescence or has a role in SASP regulation is unknown.
5. Telomere dysfunction in lung ageing and disease
Telomere dysfunction is strongly implicated in induction and
maintenance of cellular senescence. While studies describe increased
markers of senescence in the lungs with age, the role of telomere dys-
function is less well documented. Our lab has found that TAF increase
in the airway epithelium of the murine lung with age (Birch et al.,
2015). However, signiﬁcant changes to telomere length were not de-
tected. Mice ubiquitously express telomerase and have long telomeres,
therefore telomere shortening may not play a major role in murine lung
ageing. In fact, we have previously reported that while TAF sig-
niﬁcantly correlated with emphysematous-like changes in the murine
lung with age, telomere length did not (Birch et al., 2015). In contrast,
telomere shortening and telomere dysfunction may heavily inﬂuence
the ageing human lung, however little research into telomere dys-
function and physiological human lung ageing exists.
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5.1. Telomere dysfunction in COPD
In contrast to physiological lung ageing, telomere dysfunction is
well-documented in a number of age-related lung diseases, such to a
degree that they have been dubbed “telomere disorders” (Adnot et al.,
2015). A number of studies have described accelerated telomere
shortening in circulating leukocytes from patients with COPD (Houben
et al., 2009; Mui et al., 2009). Savale and colleagues have shown that
telomere length in circulating leukocytes of patients with COPD nega-
tively correlates with plasma IL-6 levels (Savale et al., 2009). Inter-
estingly, a dose-dependent relationship between smoking history and
telomere length of circulating lymphocytes has also been described
(Morla et al., 2006). In one study of over 40,000 individuals, shorter
telomere length was associated with decreased lung function and in-
creased risk of COPD (Rode, Bojesen, Weischer,
Vestbo, & Nordestgaard, 2013). However, other studies have failed to
ﬁnd associations between telomere length and FEV1 or smoking history
(Houben et al., 2009; Savale et al., 2009). Additionally, accelerated
telomere shortening has been described in resident lung cells in patients
with COPD, including type II alveolar cells and endothelial cells (Tsuji
et al., 2006). In contrast, our group has previously reported a signiﬁcant
increase in TAF in small airway epithelial cells of patients with COPD,
without signiﬁcant changes in telomere length detected (Birch et al.,
2015). It is highly plausible that both telomere shortening and length-
independent telomere damage occur in the lungs of patients with
COPD, since imbalances in oxidative stress and anti-oxidant defenses
are a major feature of the disease (Houben et al., 2009), with telomeres
being particularly susceptible to oxidative modiﬁcations and less eﬃ-
ciently repaired compared to the rest of the genome (Hewitt et al.,
2012; Petersen et al., 1998; Richter & von Zglinicki, 2007). Indeed,
there are an estimated 1014–17 oxidative particles per puﬀ of cigarette
smoke and patients with COPD show increased markers of oxidative
stress both systemically and in the lung (Kirkham& Barnes, 2013;
MacNee, 2001). Levels of 4-hydroxy-2-nonenal (4-HNE) (a lipid per-
oxidation end-product that reacts with extracellular proteins forming
adducts) modiﬁed proteins were increased in airway and alveolar epi-
thelial cells, endothelial cells and neutrophils present in lung tissue
from patients with COPD (Rahman et al., 2002). Both RNA and DNA
oxidation have been described in the alveolar walls of patients with
COPD (Deslee et al., 2009). A common byproduct of guanine oxidation
by ROS and reactive nitrogen species is 8-hydroxy-2′-deoxyguanosine
(8-OHdG) (Kasai, 1997). 8-OHdG is increased in the peripheral lungs of
patients with COPD and smokers without COPD (Caramori et al., 2011;
Tzortzaki et al., 2012). The high proportion of guanine triplets within
telomere repeats in addition to their remarkable sensitivity to oxidative
modiﬁcations suggests that telomeres could be the likely site of 8-OHdG
occurrence. Accordingly, exposure to CSE leads to telomere shortening
and TAF in embryonic stem cells, ﬁbroblasts and airway epithelial cells
in vitro (Birch et al., 2015; J. Huang et al., 2013) and in vivo exposure to
cigarette smoke leads to increased TAF in the murine lung (Birch et al.,
2015). In addition, exposure to cigarette smoke increases 8-OHdG and
4-HNE in the lungs of mice (Aoshiba et al., 2003; Yao et al., 2014).
These ﬁndings suggest that telomere-associated damage is highly im-
portant to the pathogenesis of COPD – the properties of telomeres that
Fig. 3. Simpliﬁed depiction of key metabolic pathways and their involvement in cellular senescence. A number of metabolic processes have been found to be altered in cellular senescence
(highlighted in red text). Glycolysis, which takes place in the cytosol and leads to the generation of pyruvate from glucose, is increased in senescent cells in culture. Pyruvate metabolism
has also been implicated in cellular senescence. Pyruvate serves as the primary carbon source for acetyl-CoA, which feeds into the tricarboxylic acid (TCA) cycle; a series of reactions that
take place in the matrix of the mitochondria to generate energy and NADH for use in the electron transport chain (ETC). While the ETC leads to generation of ATP, it is also the major
source of mitochondrial reactive oxygen species (ROS). A number of intermediates are generated during the TCA cycle (not all are shown for simplicity) which have roles in various
biological processes, such as amino acid and fatty acid synthesis. Malate, produced from fumarate by fumarase, is decarboxylated to pyruvate via mitochondrial malic enzyme 2 (ME2).
ME2 expression is also altered in senescent cells. Changes in metabolic processes leading to alterations in NAD+: NADH and AMP/ADP:ATP ratios impact on enzymes such as poly-ADP-
ribose polymerases (PARPs) and sirtuins, which are dependent on NAD+, and AMP-activated protein kinase (AMPK), which responds to high levels of AMP and ADP. PARPs are the main
repairers of genotoxic stress-induced damage while sirtuins impact on senescence in various ways, including regulating NF-κB activity and in maintaining transcriptionally silent
chromatin of NF-κB-dependent genes, such as SASP factor transcripts. AMPK promotes cell cycle arrest by impacting on activity and stability of cyclin-dependent kinase inhibitors p53,
p21 and p16. DDR, DNA damage response; SASP, senescence-associated secretory phenotype; NF-κB, nuclear factor-κB.
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render them particularly susceptible to oxidative damage, plus protec-
tion from repair activities at telomere regions, places telomeres as key
signalers of damage occurring as a consequence of cigarette smoke
exposure and during the aging process.
5.2. Telomere dysfunction in IPF
One of the major indicators of telomeres being particularly im-
portant to development of chronic lung disease comes from studies
using mouse models of telomere dysfunction. In two murine models of
telomere dysfunction, whereby telomeres were critically short (telo-
merase-deﬁcient mice) or a DNA damage response was activated at
telomere regions without shortening (TRF1 deletion in type II alveolar
cells), pulmonary ﬁbrosis developed (Povedano, Martinez, Flores,
Mulero, & Blasco, 2015). In patients with pulmonary ﬁbrosis, telomere
shortening is detectable in circulating leukocytes (Alder et al., 2008)
and in alveolar type II cells in the lungs of patients with sporadic and
familial pulmonary ﬁbrosis (Alder et al., 2008). In addition, levels of
TAF increase signiﬁcantly in alveolar cells in lung tissue from patients
with IPF as compared to controls (Schafer et al., 2017). However, some
of the most compelling evidence for telomere shortening and dysfunc-
tion contributing to IPF, and COPD alike, comes from genetic studies
showing that mutations in telomere-related genes are common in pa-
tients with familial pulmonary ﬁbrosis and severe emphysema. Arma-
nios et al. found that mutations in hTERT and hTR, the RNA component
of telomerase, were common in patients with familial pulmonary ﬁ-
brosis and lead to shorter leukocyte telomere length in these patients
(Armanios et al., 2007). Similarly, deleterious mutations in hTERT have
been found in cohorts of patients with severe COPD and have been
identiﬁed as a risk factor for emphysema susceptibility in smokers,
showing an autosomal dominant inheritance pattern in families
(Stanley et al., 2015). Interestingly, an observational study of 149 pa-
tients with IPF found that shorter telomere length in circulating leu-
kocytes was associated with a reduced transplant-free survival time
(Stuart et al., 2014).
5.3. Telomere dysfunction in bronchiectasis and asthma
While limited studies are available investigating the role of telo-
meres in bronchiectasis and asthma, there are some data to suggest that
telomere dysfunction may be involved in the pathogenesis of these
diseases. Our lab has recently discovered that large airway epithelial
cells in the bronchiectatic lung have shortened telomeres compared to
aged-matched controls and a signiﬁcantly higher number of TAF (Birch
et al., 2016). Given this is the only documented investigation into tel-
omere health in bronchiectasis, further research is required to under-
stand the importance of this observation. Telomere shortening has been
documented in circulating leukocytes from adults with asthma (Hadj
Salem, Dube, Boulet, & Chakir, 2015). Accordingly, life-long persistent
asthma is characterised by shorter leukocyte telomere length in com-
parison to childhood- and adult-onset, non-persistent asthma, sug-
gesting telomere shortening could be important to disease chronicity
(Belsky et al., 2014). However, the relevance of these observations to
the cells directly involved in the disease process in the airways of
asthmatics is unknown, since no published studies have examined tel-
omere function in resident lung cells in the asthmatic lung. Our group
has found that large airway epithelial cells have signiﬁcantly more TAF
in a small cohort of patients with adult-onset asthma as compared to
controls (unpublished). Further research into the role of telomere dys-
function in the development and progression of asthma is required.
While some markers of cellular senescence are increased in the lungs of
patients with CF, telomere shortening was not detected in all patients
(Fischer et al., 2013). Further study into telomere length and dysfunc-
tion in the CF lung and in circulating leukocytes of patients with CF is
warranted.
6. Mitochondria in lung ageing and dysfunction
The mitochondria are particularly important for several features of
the senescence state (Correia-Melo et al., 2016). In addition, altered
mitochondrial homeostasis is documented in the healthy lung with age,
including increases in mitochondrial mass and frequencies of fused
mitochondria (Bueno et al., 2015), impaired respiration and increased
mitochondrial-derived ROS (Braidy et al., 2011). Moreover, a number
of mitochondrial changes associated with senescence occur in age-re-
lated lung diseases, including in COPD and IPF. Therefore, under-
standing the mechanisms behind mitochondrial dysfunction could oﬀer
potential therapeutic avenues for treatment of age-related lung dys-
function and chronic lung disease.
Since it is diﬃcult to discern whether mitochondrial-derived ROS
per se are upregulated in the lungs of patients with chronic lung disease,
the majority of data implicating mitochondrial ROS in COPD is in iso-
lated cells. For instance, exposure to CSE has been shown to increase
mitochondrial-derived ROS in vascular endothelial cells and lung ﬁ-
broblasts (Birch et al., 2015; Csiszar et al., 2008), which can be su-
pressed by cultivation of cells under low oxygen concentrations, also
limiting TAF and Sen-β-Gal activity (Birch et al., 2015). Additionally,
airway smooth muscle cells from patients with COPD produce greater
amounts of mitochondrial-derived ROS compared to controls at base-
line and following inﬂammatory stress, such as treatment with IL-1 or
TNF-α (Wiegman et al., 2015). Nevertheless, since markers of oxidative
stress are upregulated in the lungs of patients with COPD and mi-
tochondria are the main producers of ROS within the cell, it is highly
likely that mitochondrial ROS are a major source of COPD-associated
oxidative stress. Indeed, in the ozone-induced mouse model of COPD,
airway hyper-responsiveness and inﬂammation was attenuated by the
mitochondrial-targeted antioxidant Mito-Q (Wiegman et al., 2015).
Increased oxidative stress has also been described in IPF. Hecker and
colleagues showed that ROS-generating NADPH oxidase-4 (NOX-4) is
up-regulated in IPF lung tissue and in IPF-derived lung ﬁbroblasts,
along with other markers of senescence (Hecker et al., 2014). Inter-
estingly, in aged mice, pharmacological inactivation of NOX-4 attenu-
ates myoﬁbroblast senescence and reverses persistence of ﬁbrosis
(Hecker et al., 2014). These results suggest that restoring redox
homeostasis, or interfering with other key eﬀectors of senescence, could
ameliorate age-related ﬁbrotic phenotypes.
Changes in mitochondrial morphology have been described in the
ageing lung and in age-related lung disease. Bronchial epithelial cells
from patients with COPD harbour swollen, elongated mitochondria in
addition to fragmentation and disruption of cristae (Hoﬀmann et al.,
2013). Moreover, treatment of human bronchial epithelial cells with
CSE leads to long-term changes in mitochondrial structure (Hoﬀmann
et al., 2013) and causes mitochondrial fragmentation (Hara et al.,
2013). Interestingly, PGC1-α-mediated mitochondrial biogenesis is in-
creased in mild COPD but levels of PGC1-α steadily decrease with in-
creasing COPD severity (Li, Dai, Hu, Zhu, & Tan, 2010). Increased mi-
tochondrial mass observed following CSE exposure could be due to
decreases in mitophagy, since key mitophagy-mediating factors like
Parkin are reduced in the lungs of patients with COPD and non-COPD
smokers (Ahmad et al., 2015; S. Ito et al., 2015). In addition, knock-
down of Parkin and its activator PTEN-induced putative kinase 1
(PINK1), which are responsible for promoting mitophagy of damaged
mitochondria, leads to increased mitochondrial ROS produced as a
consequence of CSE exposure (S. Ito et al., 2015) In contrast, some
reports describe an increase in Parkin and PINK1 in airway epithelial
cells from the COPD lung, however this could be a compensatory eﬀect
(Hoﬀmann et al., 2013; Mizumura et al., 2014). However, PINK1−/−
mice are protected against mitochondrial dysfunction and airspace
enlargement following exposure to cigarette smoke (Mizumura et al.,
2014), suggesting that mitophagy-dependent events are dis-
advantageous in the development of emphysema following cigarette
smoke exposure (Mizumura et al., 2014). In the IPF lung, Bueno and
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colleagues showed that type II alveolar epithelial cells harbour dys-
morphic and dysfunctional mitochondria with reduced expression of
PINK1 (Bueno et al., 2015). Hawkins and colleagues also demonstrated
that mutations causing defective clearance of mitochondria are linked
to familial pulmonary ﬁbrosis (Hawkins et al., 2015). In addition, re-
search by Patel and collaborators demonstrated that PINK1-deﬁcient
mice have enhanced susceptibility to pulmonary ﬁbrosis (Patel et al.,
2015). This could suggest that mitochondrial dysfunction could be
mediated, in part, by impaired mitophagy as a consequence of cigarette
smoke exposure or during disease progression. However, further work
is required to fully elucidate the role of mitophagy in age-related lung
disease, since reports are conﬂicting; something that has previously
been described with autophagy being beneﬁcial in some instances,
while detrimental in others (Korolchuk et al., 2017).
Intricate changes in mitochondrial metabolism, such as shifts in
glycolysis or TCA cycle activity are relatively understudied in the
ageing lung and in age-related respiratory diseases. In a model of pro-
gressive murine emphysema, L-carnitine was found to be signiﬁcantly
reduced (Conlon et al., 2016). Carnitine is involved in fatty acid
transfer into the mitochondria, which may suggest that alterations in
fatty acid metabolism are linked to mitochondrial dysfunction in cer-
tain pathologies, such as emphysema. In another study, it was found
that knockdown of iron-responsive element-binding protein 2 (IRP2)
protected mice from development of CS-induced COPD (Cloonan et al.,
2016). IRP2 increases mitochondrial iron loading and mitochondrial
dysfunction through elevating levels of mitochondrial cytochrome C
oxidase, which then causes COPD (Cloonan et al., 2016). Mice on a low-
iron diet or treated with an iron chelator were protected against CS-
induced inﬂammation and lung injury, suggesting that the mitochon-
drial-iron axis is important to development of cigarette smoke-induced
COPD (Cloonan et al., 2016). Changes in NAD+/NADH ratios occur in
cellular senescence. Reductions in NAD+-dependent SIRT1, SIRT3 and
SIRT6 have been implicated in COPD and IPF, respectively (Birch et al.,
2015; Nakamaru et al., 2009; Rajendrasozhan, Yang,
Kinnula, & Rahman, 2008; Sosulski, Gongora, Feghali-Bostwick,
Lasky, & Sanchez, 2017). SIRT1 is decreased in the airway epithelium
and peripheral lung of patients with COPD (Birch et al., 2015;
Nakamaru et al., 2009; Rajendrasozhan et al., 2008). Moreover, CSE
reduces SIRT1 expression in vitro (Caito et al., 2010; Rajendrasozhan
et al., 2008). SIRT6 is also reduced in the COPD lung, in isolated small
airway epithelial cells from COPD patients, and following exposure to
oxidative stress in vitro (Baker et al., 2016; Nakamaru et al., 2009).
Levels of SIRT3 are decreased in ﬁbrotic regions of the IPF lung and
SIRT3 deﬁciency has been shown to augment pulmonary ﬁbrosis in
mice (Sosulski et al., 2017). SIRT1 is also reduced in the epithelium of
patients with bronchiectasis (Birch et al., 2016). Sirtuins are involved in
histone and protein post-translational modiﬁcations and SIRT1 su-
presses the expression of SASP factors via histone deacetylation at their
promoter regions and via deacetylation of NF-κB (Hayakawa et al.,
2015). Interestingly, it was reported that pharmacological inhibition of
histone deacetylases ameliorates bleomycin-induced pulmonary ﬁbrosis
in mice (Sanders et al., 2014), suggesting that activation or inhibition of
sirtuins is a potential therapeutic option in chronic lung disease, which
may be disease- or severity-dependent. In line with this, a sirtuin-acti-
vating compound is able to prevent the decrease in SIRT1 that occurs in
mice following cigarette smoke exposure, while also inhibiting neu-
trophilic inﬂammation in the lung (Nakamaru et al., 2009).
How the mitochondrial metabolome is altered in the ageing lung or
in conditions of accelerated lung ageing is largely unknown. Some data
suggests that cigarette smoke exposure leads to reduced glycolytic ac-
tivity in vitro (Agarwal et al., 2012). Whereas, cigarette smoke exposure
leads to increases in succinate dehydrogenase (SDH) gene expression in
the murine lung (Agarwal et al., 2012). Moreover, citrate synthase
activity is reduced in muscle from patients with COPD (Konokhova
et al., 2016). Research into the role of glycolysis and TCA cycle activity
is required in lung ageing and disease, since the mitochondria are
particularly important in regulating a number of cellular functions and
alterations in mitochondrial metabolism may be linked to SASP mod-
ulation.
As previously mentioned, mtDNA is an immunustimulatory factor
that could potentially be important to senescence and senescence-as-
sociated inﬂammation. Interestingly, CSE exposure causes DAMP re-
lease from neutrophils, including HMGB1 and mtDNA, inducing innate
immune responses (Heijink et al., 2015; Pouwels et al., 2016). More-
over, mtDNA is increased in saliva of smokers, even decades after
smoking cessation, suggesting long-term changes induced by cigarette
smoke exposure (Masayesva et al., 2006). Asthma-COPD overlap syn-
drome (ACOS) is a respiratory condition including features of both
COPD and asthma (Barnes, 2016a, 2016b). Levels of mtDNA are in-
creased relative to nuclear DNA in the blood of patients with ACOS.
While the role of DAMPs, including mtDNA, in IPF have not particularly
been studied, it has been shown that activation of the NLRP3 in-
ﬂammasome, a sensor of cytosolic mtDNA, is relevant to the develop-
ment of lung ﬁbrosis, since deﬁciency of NLRP3 diminishes bleomycin-
induced lung injury in aged animals (Stout-Delgado et al., 2016). Un-
derstanding whether mtDNA acts as an immunostimulatory factor, or
contributes to senescence, in the context of chronic lung disease may
therefore be of therapeutic interest.
7. Therapeutic opportunities
There is currently no cure for chronic inﬂammatory lung diseases
like COPD and IPF, and the use of anti-inﬂammatories has in general
lead to disappointing results. Numerous studies strongly support the
concept that cellular senescence is involved in the pathogenesis of
COPD and IPF, and is potentially relevant to other respiratory condi-
tions. Therefore, therapies that harness pathways involved in cellular
senescence may be on the horizon for respiratory diseases (Barnes,
2017). While oxidative stress is a major feature of COPD, the use of
anti-oxidants such as N-Acetyl Cysteine (NAC) has not produced clear
beneﬁts in trials and only has moderate eﬀects on patients with COPD
(Shen, Cai, Lei, & Zhang, 2014). This is possibly due to the fact that NAC
is inactivated by high levels of oxidative stress, hence more eﬀective
antioxidants are required. Indeed, novel, more stable, anti-oxidants are
now being considered including SOD mimetics and Nrf2 activators
(Barnes, 2017) Indeed, restoration of the NOX4-Nrf2 redox imbalance
was suﬃcient to reverse persistent ﬁbrosis, at least in mice (Hecker
et al., 2014).
Studies demonstrating genetic elimination of already senescent cells
have provided a proof-of-concept that removal of senescent cells could
be a viable therapy for treating aspects of age-related functional de-
cline, age-related diseases or potential side-eﬀects of therapies that lead
to the generation of senescent cells. While Baker and colleagues have
demonstrated that genetic elimination of p16INK4a-positive senescent
cells delays onset of a number of age-related pathologies and extends
lifespan during accelerated and physiological ageing (Baker et al.,
2011; Baker et al., 2016), the same transgenic mouse model has also
been utilised to demonstrate that removal of senescent cells can im-
prove lung function and ﬁtness of mice with pulmonary ﬁbrosis fol-
lowing bleomycin injury (Schafer et al., 2017). In both of these studies
no overt side eﬀects of senescent cell clearance were reported. Genetic
elimination of senescent cells is an unlikely viable strategy in humans.
However, the development of pharmacological drivers of senescent-cell
apoptosis, known as senolytics, oﬀers a potential alternative. Senolytics
act by inhibiting pro-survival and anti-apoptotic proteins that are spe-
ciﬁcally upregulated in senescent cells. It has been shown in vitro that a
combination of dasatinib, a tyrosine kinase inhibitor, and quercetin, a
ﬂavanoid and inhibitor of phosphatidylinositol-4,5-bisphosphate 3-ki-
nases (PI3Ks), (D+Q) reduces expression of BCL-xL in both senescent
pre-adipocytes and HUVEC cells (Zhu et al., 2016). D+Q has also been
shown to reduce senescent cell burden in aged, radiation-exposed and
progeroid mice and improves healthspan, including cardiac function
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(Zhu et al., 2015). D+Q administration reduces senescent cell fre-
quencies and improves established age-associated vascular phenotypes,
such as aortic calciﬁcation, in aged and hypercholesterolaemic mice
(Roos et al., 2016). Interestingly, D+Q administration improves the
health of mice with pulmonary ﬁbrosis to the same degree as genetic
elimination of senescent cells (Schafer et al., 2017) and has been shown
to reduce ﬁbrotic burden and key SASP factors, while upregulating
markers of type II alveolar epithelial cells, in an ex vivo model of pul-
monary ﬁbrosis derived from mice treated with bleomycin (Lehmann
et al., 2017). ABT-263, otherwise known as navitoclax, is an inhibitor of
the BCL-2 family, which has been shown to induce apoptosis in senes-
cent HUVECs, human and murine ﬁbroblasts in vitro (Zhu et al., 2016).
Navitoclax has also been shown to eﬀectively deplete senescent cells,
including senescent bone marrow hematopoietic stem cells and senes-
cent muscle stem cells, in sub-lethally irradiated and physiologically
aged mice (Chang et al., 2016). Moreover, navitoclax has recently been
shown to reverse pulmonary ﬁbrosis induced by thoracic irradiation in
mice (Pan et al., 2017). These results suggest that senolytics could be a
viable option for treatment of pathologies involving cellular senes-
cence, including age-related lung disease. Strengthening this notion are
data from Schafer and colleagues that showed both early administration
of senolytics, at onset of disease pathogenesis, and administration at a
later time point when the pathology had fully developed, lead to ben-
eﬁcial eﬀects (Schafer et al., 2017). This suggests that senescent cell
clearance may be beneﬁcial even at later stages of disease progression.
Whether senolytics are beneﬁcial in mouse models of COPD still needs
to be determined. It must be noted that the potential pitfalls of senolytic
drug use are still not fully understood, with possible “side eﬀects”
suspected in non-senescent healthy cells (Birch & Passos, 2017). In ad-
dition, senolytics have shown cell speciﬁcity in their apoptosis-inducing
eﬃcacy (Zhu et al., 2016) and so determining the senolytic of choice,
depending on the senescent cell type involved, adds another layer of
complexity. This point particularly resonates for diseases where mul-
tiple cell types are involved in the senescence programme, as has been
described in COPD and IPF. Another potential option could be to har-
ness the immune system to induce senescent cell clearance by im-
munotherapy methods. Studies have provided strong evidence to sug-
gest that components of the immune system are responsible for
senescent cell clearance. While no current data exit showing immune-
mediated clearance of senescent cells induced by speciﬁc activation of
the immune response, such as using a senescence-associated peptide or
DAMP, it is a possibility that the immune system could be driven in this
direction in a similar manner to cancer immunotherapy. Senescence has
some beneﬁcial eﬀects, as previously alluded to, therefore complete
removal of senescent cells may not be desirable. This is also the case in
the context of lung ageing and disease, since some studies show that
senescence is beneﬁcial in proliferative diseases such as cancer and
pulmonary hypertension (PH). Inducing cellular senescence by blocking
p53 inactivation prevented and reversed PH in animal models
(Mouraret et al., 2013). Furthermore, telomerase inactivation in mice
reduces the severity of experimental PH, by inhibiting cell proliferation
and by promoting senescence in pulmonary vascular smooth muscle
cells (Mouraret et al., 2015). PH is a common feature of both COPD and
IPF and the presence of PH is associated with a poorer prognosis,
therefore the use of senolytic therapies would need to be very carefully
considered. Moreover, around one-third of patients with COPD die from
lung cancer and IPF patients also have increased cancer risk, which is
an important consideration when advocating anti-senescence therapies
for use in these diseases.
Interfering with pathways important to senescence regulation, such
as those that orchestrate SASP modulation, could be a better strategy,
or indeed, inhibition of SASP factors themselves. The mTOR pathway
has previously been considered a potential druggable target for age-
related lung disease. Inhibition of mTOR with rapamycin has been
shown to increase lifespan in various model organisms (Harrison et al.,
2009; Miller et al., 2011) and attenuates a number of age-related
changes in mice (Wilkinson et al., 2012). It has previously been sug-
gested that the beneﬁcial eﬀects of rapamycin in vivo could be due to its
ability to acts as a SASP suppressor, since rapamycin inhibits IL-1
translation and reduces stability of SASP factor mRNA transcripts in
vitro (Herranz et al., 2015; Laberge et al., 2015). Indeed, mTOR activity
is upregulated in the murine lung with age (Calhoun et al., 2016) and in
ﬁbroblasts from patients with IPF (Romero et al., 2016). Moreover,
Calhoun and colleagues demonstrated that rapamcyin reduces collagen
deposition that occurs in the murine lungs with age, along with redu-
cing senescent cell frequencies (Calhoun et al., 2016). The role of mTOR
in COPD is less well deﬁned, however our lab have found that inhibition
of mTOR with rapamycin reduces the SASP induced following CSE
exposure (unpublished). Similar results have been documented in mice
(Yoshida et al., 2010). Additionally, metformin, which activates the
AMP kinase and subsequently inhibits mTOR has beneﬁcial eﬀects in
patients with COPD. The safety of metformin in patients with COPD and
type 2 diabetes mellitus was assessed recently, and improved patient
survival was documented (Hitchings, Archer, Srivastava, & Baker, 2014;
Sexton, Metcalf, & Kolbe, 2014). Moreover, mTOR activation has been
described in peripheral blood mononuclear cells from patients with
COPD, with rapamycin treatment restoring corticosteroid sensitivity
(Mitani, Ito, Vuppusetty, Barnes, &Mercado, 2016). Furthermore, a
prospective study showed improvements in some symptoms and health
status of patients with COPD given metformin for 6 months (Sexton
et al., 2014). Therefore, rapamycin and metformin use could potentially
be beneﬁcial in COPD. Additionally, the use of a combined mTOR and
PI3K inhibitor, known as GSK2126458, reduces pro-ﬁbrotic collagen
formation in IPF lung tissue slices (Mercer et al., 2016), suggesting that
mTOR inhibition could be considered as a method to interfere with
ﬁbrogenic signaling in IPF. This is in line with another study showing
beneﬁcial eﬀects of targeting the PI3K/AKT/mTOR pathway with ra-
pamycin and PP42 in IPF-derived ﬁbroblasts, which activated autop-
hagy and induced apoptosis in usually apoptosis-resistant IPF ﬁbro-
blasts under conditions of serum starvation (Romero et al., 2016).
Whether these drugs could act as novel senolytics under certain con-
ditions should be further investigated. Indeed, another study demon-
strated that inhibition of the SASP factor PAI-1, which is overexpressed
in murine lung ﬁbroblasts with age and following bleoymycin chal-
lenge, eliminated resistance to apoptosis in ﬁbroblasts derived from
ﬁbrotic murine lungs (W. T. Huang et al., 2015). It could be possible
therefore that targeting of key SASP factors, some of which are known
to maintain senescence in an autocrine fashion (Acosta et al., 2008), is a
form of senotherapy that should be explored. Mitochondria-targeted
therapies, including regulation of mitophagy, altering mitochondrial
homeostasis or impacting on mitochondrial biogenesis are other pos-
sible alternatives. To this end, inhibitors of mitochondrial ﬁssion such
as the DRP1 inhibitor Mdivi-1 have been shown to rescue abnormal
mitochondrial processes in models of COPD (Mizumura et al., 2014).
Interestingly, in murine cancer models, alterations in amino acid
availability, such as serine and glycine starvation reduces tumour
growth and leads to improved survival (Maddocks et al., 2017). While
only limited data exist suggesting alterations in the mitochondrial
metabolome in lung disease, mechanisms underlying these changes
may potentially be exploited for the development of future therapies for
respiratory disease, particularly since evidence suggests that alterations
in mitochondrial function may impact on speciﬁc SASP factors (Correia-
Melo et al., 2016). However, the exact roles of these processes in lung
ageing and disease must ﬁrst be elucidated.
The future is bright for the generation of innovative therapies to
treat age-related respiratory diseases, such as COPD and IPF, with
therapeutic advances likely to extend to other lung conditions (Fig. 4).
The comorbidities associated with COPD and IPF are also largely due to
accelerated ageing and appear to share common molecular pathways.
Therefore, it is possible that therapies could be developed that would
also treat associated comorbidities, such as cardiovascular disease and
type 2 diabetes (Barnes, 2015). Other respiratory disorders that could
J. Birch et al. Pharmacology and Therapeutics xxx (xxxx) xxx–xxx
11
potentially beneﬁt from senotherapies include pathologies arising fol-
lowing lung transplantation, such as bronchiolitis obliterans syndrome
(BOS) (Parker et al., 2008) and senescence-related pathologies arising
following lung cancer treatment. Indeed, a recent study has demon-
strated that a cell penetrating peptide (CPP) designed around a speciﬁc
amino acid sequence excludes p53 from the nucleus of senescent cells
and induces apoptosis. This CPP is also able to reduce doxorubicin-in-
duced chemo-toxicity in vivo (Baar et al., 2017), suggesting that anti-
senescence therapies may be useful to counteract senescence induced
by cancer therapy. While the use of senolytics for treatment of age-
related disease is an attractive concept, and no overt side eﬀects have
been recorded in control mice or ex vivo lung tissues when administered
in the context of pulmonary ﬁbrosis (Lehmann et al., 2017; Schafer
et al., 2017), reports of undesirable side-eﬀects have been recorded in
human cancer patients, including thrombocytopenia (Rudin et al.,
2012). Hence, the full extent of the oﬀ-target eﬀects of senolytics needs
to be uncovered. Another area for consideration relates to the beneﬁcial
functions of senescent cells that have been identiﬁed. Therefore the
context in which senescent cells are targeted needs to be carefully ﬁne-
tuned. Molecules that interfere with regulatory processes active in se-
nescent cells, such as those that govern the SASP, may be a better al-
ternative. The use of aged and senescence-prone mice, which have so
far shown to recapitulate some of the key features of human respiratory
disease, to conduct preclinical studies of such interventions is an ex-
citing possibility. However, how humans and mice diﬀer in the key
processes that regulate senescence, such as mTOR signalling and mi-
tochondrial metabolism, needs to be determined if any of the described
senotherapies are to be truly translational to humans. The roles of such
processes in governing cellular senescence in relation to age-related
lung disease also requires further study, and whether senescence is an
important process contributing to the pathogenesis of respiratory dis-
eases not typically associated with ageing, such as CF and asthma,
needs also to be clearly understood.
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